Trends of drug resistance in M. tuberculosis in a reference laboratory in Central India: Forging ahead towards TB elimination

IF 1.4 4区医学 Q4 IMMUNOLOGY

Indian Journal of Medical Microbiology Pub Date : 2024-08-14 DOI:10.1016/j.ijmmb.2024.100701

Prabha Desikan , Nikita Panwalkar , Aseem Rangnekar , Zeba Khan , Ram Prakash Punde , Arun Kumar Sharma , Ragini Kushwaha , Chinnaiyan Ponnuraja , Sridhar Anand

{"title":"Trends of drug resistance in M. tuberculosis in a reference laboratory in Central India: Forging ahead towards TB elimination","authors":"Prabha Desikan , Nikita Panwalkar , Aseem Rangnekar , Zeba Khan , Ram Prakash Punde , Arun Kumar Sharma , Ragini Kushwaha , Chinnaiyan Ponnuraja , Sridhar Anand","doi":"10.1016/j.ijmmb.2024.100701","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The National Tuberculosis Elimination Programme (NTEP) of the Government of India has strived to control tuberculosis (TB) in the country through various interventions. Understanding the trends of resistance patterns may provide insights into the effectiveness of TB control activities in the country.</p></div><div><h3>Methods</h3><p>A total of 31,144 clinical samples were received from 2013 to 2022 from presumptive drug-resistant TB patients. All the specimens were decontaminated and subjected to the line probe assay for detection of resistance to rifampicin and isoniazid. <em>Mycobacterium tuberculosis</em> (MTB) was detected in 28,814 samples. Autoregressive integrated moving average model (ARIMA) was fitted to assess the trend over time.</p></div><div><h3>Results</h3><p>A decreasing trend in multi-drug resistant TB from 19 % in 2013 to 4 % in 2022 was seen. A decreasing trend in rifampicin monoresistance from 11.2 % in 2013 to 1.5 % in 2022 was seen, though there was an increase in resistance in 2017. No significant decreasing trends were seen in the proportion of isoniazid monoresistance from 8.3 % in 2013 to 7 % in 2022.</p></div><div><h3>Conclusion</h3><p>The findings are encouraging, and to a considerable extent, affirm that India is well on track with regard to the goal of TB elimination.</p></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"51 ","pages":"Article 100701"},"PeriodicalIF":1.4000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085724001762","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The National Tuberculosis Elimination Programme (NTEP) of the Government of India has strived to control tuberculosis (TB) in the country through various interventions. Understanding the trends of resistance patterns may provide insights into the effectiveness of TB control activities in the country.

Methods

A total of 31,144 clinical samples were received from 2013 to 2022 from presumptive drug-resistant TB patients. All the specimens were decontaminated and subjected to the line probe assay for detection of resistance to rifampicin and isoniazid. Mycobacterium tuberculosis (MTB) was detected in 28,814 samples. Autoregressive integrated moving average model (ARIMA) was fitted to assess the trend over time.

Results

A decreasing trend in multi-drug resistant TB from 19 % in 2013 to 4 % in 2022 was seen. A decreasing trend in rifampicin monoresistance from 11.2 % in 2013 to 1.5 % in 2022 was seen, though there was an increase in resistance in 2017. No significant decreasing trends were seen in the proportion of isoniazid monoresistance from 8.3 % in 2013 to 7 % in 2022.

Conclusion

The findings are encouraging, and to a considerable extent, affirm that India is well on track with regard to the goal of TB elimination.

查看原文本刊更多论文

印度中部参考实验室结核杆菌的耐药性趋势：向消灭结核病迈进。

目的：印度政府的国家消除结核病计划（NTEP）一直在努力通过各种干预措施控制该国的结核病（TB）。了解耐药性模式的趋势有助于深入了解该国结核病控制活动的有效性：从 2013 年到 2022 年，共收到 31,144 份临床样本，这些样本来自推定耐药的肺结核患者。所有样本都经过净化，并采用线探针检测法检测对利福平和异烟肼的耐药性。在 28,814 份样本中检测到了结核分枝杆菌（MTB）。采用自回归综合移动平均模型（ARIMA）评估随时间变化的趋势：耐多药结核病呈下降趋势，从 2013 年的 19% 降至 2022 年的 4%。利福平单耐药率呈下降趋势，从2013年的11.2%降至2022年的1.5%，但2017年耐药率有所上升。异烟肼单耐药性的比例从2013年的8.3%下降到2022年的7%，但没有明显的下降趋势：研究结果令人鼓舞，在很大程度上证明印度在实现消除结核病的目标方面进展顺利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.